PRESS COVERAGE19 Feb 2024 11:53
(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.
Shares in Evgen Pharma were up 11% to 1.16 pence each in London on Monday before midday.
The clinical stage drug development company developing sulforaphane-based medicines said the laboratory of Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells.
"We have seen continued evidence of biological activity in patient-derived glioblastoma tissue," said Geurts.
Evgen Pharma said the in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a EUR1.1 million project, are designed to investigate the activity of SFX-01 in preclinical GBM models.
This work is to be followed by administration of SFX-01 to patients with GBM in a clinical investigator sponsored study. The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period.